加拿大7价和13价肺炎球菌结合疫苗的疫苗有效性:一项IMPACT研究
该研究采用间接队列分析,评估2002至2018年加拿大5岁以下儿童接种7价和13价肺炎球菌结合疫苗(PCV)针对疫苗血清型侵袭性肺炎球菌疾病(IPD)的有效性。PCV7在按时接种儿童中单剂后有效性为96%,≥2剂后为95%;PCV13在≥2剂后有效性为55%,排除血清型3和19A后为89%。
要点
- PCV7按时接种儿童单剂后有效性96%,≥2剂后95%。
- PCV13 ≥2剂后有效性55%,排除血清型3和19A后89%。
- PCV13突破性IPD血清型以3(48.2%)和19A(40.7%)为主。
核心结论
- PCV13对血清型3和19A的有效性较低,可能受接种程序从4剂改为3剂及疫苗覆盖率80%影响,但对其他血清型仍有良好保护。
研究设计与样本
- 采用间接队列分析,纳入2002至2018年加拿大5岁以下儿童,病例来自加拿大免疫监测项目ACTive(IMPACT),该网络覆盖12家三级儿科医院,约占加拿大三级医院床位的90%。
- 评估PCV7有效性的儿童1477名,评估PCV13有效性的儿童489名。
主要发现
- PCV7在按时接种儿童中单剂后有效性96%(95% CI:67-99%),≥2剂后95%(95% CI:92-97%)。
- PCV7在已接种但未按时接种儿童中有效性91%(95% CI:85-94%)。
- PCV13在按时接种儿童中≥2剂后有效性55%(95% CI:28-72%)。
- PCV13突破性IPD血清型为3(13/27,48.2%)、19A(11/27,40.7%)和19F(3/27,11.1%)。
- 排除血清型3和19A后,PCV13对剩余疫苗血清型在≥2剂儿童中有效性89%(95% CI:64-97%)。
局限性
- PCV13有效性较低可能受接种程序从4剂改为3剂及疫苗覆盖率80%影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We used an indirect cohort analysis in children under 5 years-old from 2002 to 2018 to examine vaccine effectiveness (VE) of the 7-valent pneumococcal conjugate vaccine (PCV) (3 + 1 doses in most regions) and the 13-valent PCV (2 + 1 doses in all regions) against invasive pneumococcal disease (IPD) caused by vaccine serotypes in children in Canada. Cases were identified from the Canadian Immunization Monitoring Program ACTive (IMPACT), a national active surveillance network of 12 tertiary care pediatric hospitals that represent about 90% of tertiary care hospital beds in Canada. There were 1477 children evaluated for PCV7 VE and 489 for PCV13 VE. PCV7 VE in children with vaccination up to date for their age was 96% (95% CI: 67-99%) after a single dose and 95% (95% CI: 92-97%) after ≥2 doses. The VE was 91% (95% CI: 85-94%) in children who had received doses but were not up to date for their age. PCV13 VE in children with vaccinations up to date for their age was 55% (95% CI: 28-72%) after ≥2 doses. The PCV13-vaccine serotypes causing breakthrough IPD in children up to date for their age with 2+ doses of PCV13 were 3 (13/27, 48.2%),19A (11/27, 40.7%), and 19F (3/27, 11.1%). When serotype 3 and 19A were excluded, the VE of PCV13 against the remaining vaccine serotypes was 89% (95% CI: 64-97%) in children with ≥2 doses. The lower VE of PCV13 may be due to lower effectiveness against serotypes 3 and 19A, which could be influenced by the change in dosing schedule from 4 to 3 total doses with the introduction of PCV13, combined with vaccine uptake of 80%. However, PCV13 still provides the benefit of protection against more serotypes than PCV7, and good VE against all serotypes except 3 and 19A.
引用
- Ricketson LJ, Bettinger JA, Sadarangani M, et al. Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study. Vaccine. 2022. PMID: 35351324. doi:10.1016/j.vaccine.2022.03.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。